Biden Administration May Push Rx Pricing To Back Burner With Senate That Stays Pharma Friendly
Executive Summary
A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry.
You may also be interested in...
Biden, Germany And Bringing A National Drug Pricing Negotiation Process To US
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.
‘March In’ Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Part B Demo Comments Overwhelmingly Negative, Uniform In Content
More than 90% of comments submitted on proposed Medicare payment experiment for Part B drugs were negative, and most were submitted by patients and health care providers.